Results

Total Results: 12 records

Showing results for "buprenorphine".

1. Final Evidence Summary: Unhealthy Drug Use: Screening | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary/drug-use-illicit-screening
   June 09, 2020 - Trials of methadone or buprenorphine detoxification (withdrawal management) were excluded. … Results of trials of methadone and buprenorphine are summarized in Table 3 . … There was no significant difference between type of drug (methadone or buprenorphine), buprenorphine … Pharmacological Therapies Opioid Agonist Therapy (Buprenorphine or Methadone). … buprenorphine/naloxone.

2. Screening for Unhealthy Drug Use: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force (pdf file)
   www.uspreventiveservicestaskforce.org/home/getfilebytoken/R3y9LSud52CGL8mG4wvxoT
   June 09, 2020 - Trials of methadone or buprenorphine detoxifica- tion (withdrawal management) were excluded. … There was no significant difference between type of drug (methadone or buprenorphine), buprenorphine … Pharmacological Therapies Opioid Agonist Therapy (Buprenorphine or Methadone) | Four trials of buprenorphine … Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. … buprenorphine/naloxone.

3. Recommendation: Unhealthy Drug Use: Screening | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/recommendation/drug-use-illicit-screening
   June 09, 2020 - long-term use of opioid agonists, the US Food and Drug Administration (FDA) restricts approval for buprenorphine … was rare. 37 , 38 Seven trials assessed the opioid agonist methadone, the partial opioid agonist buprenorphine … these 2 opioid agonists (monitored for 4-12 months), use of methadone and sublingual or implantable buprenorphine … A few trials found that buprenorphine was associated with better self-reported scores on quality of life … Constipation was significantly more common in buprenorphine users than in control groups.

4. JAMA (pdf file)
   www.uspreventiveservicestaskforce.org/home/getfilebytoken/UaT8AVUSVQwSduNs8TA-_e
   June 09, 2020 - • Based on lack of evidence that these interventions cause serious adverse events and evidence that buprenorphine … long-term use of opioid ago- nists, the US Food and Drug Administration (FDA) restricts approval for buprenorphine … A few trials found that buprenorphine was associ- ated with better self-reported scores on quality of … the harms of screening in adults or adolescents.12 Pharmacotherapy Eleven naltrexone trials and 4 buprenorphine … Constipation was significantly more common in buprenorphine users than in control groups.

5. Final Research Plan: Illicit Drug Use in Children, Adolescents, and Young Adults: Primary Care-Based Interventions | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/drug-use-illicit-primary-care-interventions-for-children-and-adolescents
   August 30, 2018 - medically managed withdrawal, or medication-assisted treatment (e.g., methadone maintenance programs, buprenorphine

6. Screening For Illicit Drug Use: Recommendation Statement (pdf file)
   www.uspreventiveservicestaskforce.org/home/getfilebytoken/Qh7NQD6ZEynjyRso7L5-gS
   January 15, 2008 - Treatment: Although drug-specific pharmacotherapy (e.g., buprenorphine for opiate abuse) and/or behavioral

7. Archived: Drug Use, Illicit: Screening | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/recommendation/drug-use-illicit-screening-january-2008
   January 15, 2008 - Treatment Although drug-specific pharmacotherapy (e.g., buprenorphine for opiate abuse) and/or behavioral

8. Evidence Summary: Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/prevention-of-human-immunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis
   June 11, 2019 - that receive donated study drug from Alkermes (extended-release naltrexone) and Inidivior (sublingual buprenorphine

9. Archived: Evidence Summary: Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/prevention-of-human-immunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis-june-2019
   June 11, 2019 - that receive donated study drug from Alkermes (extended-release naltrexone) and Inidivior (sublingual buprenorphine

10. Final Evidence Summary: Hepatitis C Virus Infection in Adolescents and Adults: Screening | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary/hepatitis-c-screening
    March 02, 2020 - Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1–infected patients on methadone or buprenorphine

11. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/bQNXFv9Q5uaAQvWH6B7VWV
    June 11, 2019 - that receive donated study drug from Alkermes (extended-release naltrexone) and Inidivior (sublingual buprenorphine

12. Screening for Hepatitis C Virus Infection in Adolescents and Adults: Updated Evidence Report and Systematic Review for the USPSTF (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/WEqCV3NvnZAeLdC_pp6nVK
    October 01, 2018 - Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1–infected patients on methadone or buprenorphine